Discontinued — last reported Q1 '18
Dow Allowance for Doubtful Accounts Receivable (Current) increased by 6.8% to $63.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.2%, from $78.00M to $63.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 3.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $59.00M | $59.00M | $54.00M | $215.00M | $212.00M | $212.00M | $110.00M | $110.00M | $105.00M | $80.00M | $81.00M | $71.00M | $96.00M | $111.00M | $95.00M | $78.00M | $72.00M | $71.00M | $59.00M | $63.00M |
| QoQ Change | — | +0.0% | -8.5% | +298.1% | -1.4% | +0.0% | -48.1% | +0.0% | -4.5% | -23.8% | +1.3% | -12.3% | +35.2% | +15.6% | -14.4% | -17.9% | -7.7% | -1.4% | -16.9% | +6.8% |
| YoY Change | — | — | — | — | +259.3% | +259.3% | +103.7% | -48.8% | -50.5% | -62.3% | -26.4% | -35.5% | -8.6% | +38.8% | +17.3% | +9.9% | -25.0% | -36.0% | -37.9% | -19.2% |